PMID- 15809711
OWN - NLM
STAT- MEDLINE
DCOM- 20050712
LR  - 20091119
IS  - 1019-6439 (Print)
IS  - 1019-6439 (Linking)
VI  - 26
IP  - 5
DP  - 2005 May
TI  - FGF7-like gene is associated with pericentric inversion of chromosome 9, and FGF7 
      is involved in the development of ovarian cancer.
PG  - 1209-16
AB  - Pericentric inversion of chromosome 9 is a common chromosomal aberration that may 
      be involved in the pathogenesis of several types of cancer. Screening for 
      structural balanced chromosomal aberrations in 58 patients with ovarian carcinoma 
      found a patient with inv(9)(p11;q13) who had repeated spontaneous abortions. To 
      define the breakpoint at the 9p11 region, the human 9p11-specific CEPH-YAC 
      library was first screened with fluorescence in situ hybridization (FISH) 
      analysis, resulting in isolation of the YAC clones 961d9 and 954b9 spanning the 
      breakpoint. Next, screening with FISH analysis of the cosmid library constructed 
      from 961D9 isolated 3 cosmid clones that included the breakpoint. DNA sequence 
      analysis showed that the cosmid clones spanned the 57.7-kb sequence, which 
      contained the FGF7 [keratinocyte growth factor (KGF)]-like gene including exons 2 
      and 3. FISH analysis showed that the 57.7-kb sequence was duplicated from the 
      9p11 region to the 9q13 region on the aberrant chromosome 9. Southern blot 
      analysis showed multiple FGF7-like genes in the 9p11 region which were also 
      duplicated to the 9q13 region on the aberrant chromosome 9. Because the FGF7-like 
      genes are located at 9p11 and 9q13, our results are consistent with the 
      hypothesis that the FGF7-like genes at 9p11 and 9p13 initiate the pericentric 
      inversion of chromosome 9. Analysis of surgical specimens of ovarian cancer with 
      the reverse transcription-polymerase chain reaction and immunohistochemical 
      staining showed overexpression of the FGF7 gene in 4 of 9 stage I or II cases and 
      in 10 of 11 stage III or IV cases. These findings suggest that FGF7 plays a 
      significant role in the development of ovarian cancer.
FAU - Yasuhara, Takaomi
AU  - Yasuhara T
AD  - Food and Pharmaceutical Research and Development Laboratories, Asahi Breweries, 
      Ltd., Moriya-shi, Ibaraki 302-0106, Japan. takaomi.yasuhara@asahibeer.co.jp
FAU - Okamoto, Aikou
AU  - Okamoto A
FAU - Kitagawa, Takanori
AU  - Kitagawa T
FAU - Nikaido, Takashi
AU  - Nikaido T
FAU - Yoshimura, Tomoaki
AU  - Yoshimura T
FAU - Yanaihara, Nozomu
AU  - Yanaihara N
FAU - Takakura, Satoshi
AU  - Takakura S
FAU - Tanaka, Tadao
AU  - Tanaka T
FAU - Ochiai, Kazunori
AU  - Ochiai K
FAU - Ohtake, Yasuyuki
AU  - Ohtake Y
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (FGF7 protein, human)
RN  - 126469-10-1 (Fibroblast Growth Factor 7)
RN  - 62031-54-3 (Fibroblast Growth Factors)
SB  - IM
MH  - Abortion, Spontaneous/genetics
MH  - Blotting, Southern
MH  - Centrosome
MH  - *Chromosome Inversion
MH  - Chromosomes, Human, Pair 9/*genetics
MH  - Female
MH  - Fibroblast Growth Factor 7
MH  - Fibroblast Growth Factors/*genetics/*metabolism
MH  - *Gene Expression Regulation
MH  - Gene Library
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Ovarian Neoplasms/*genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
EDAT- 2005/04/06 09:00
MHDA- 2005/07/13 09:00
CRDT- 2005/04/06 09:00
PHST- 2005/04/06 09:00 [pubmed]
PHST- 2005/07/13 09:00 [medline]
PHST- 2005/04/06 09:00 [entrez]
PST - ppublish
SO  - Int J Oncol. 2005 May;26(5):1209-16.